A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

Other illness

• Known presence or suspicion of other neurologic disorders that may mimic MS
• Significant uncontrolled somatic diseases, known active infection or any other significant condition that may preclude participant from participating in the study
• Participants with severe cardiac disease or significant findings on the screening electrocardiograph (ECG)

Other

• -Participants who have discontinued the study during the DBP

• Body weight ≥ 25 kg
• Diagnosis of RRMS in accordance with the International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric multiple sclerosis (MS), Version 2012, or McDonald criteria 2017
• Expanded Disability Status Scale (EDSS) at screening: 0-5.5, inclusive
• For all countries except Germany, at least one MS relapse during the previous year or two MS relapses in the previous 2 years or evidence of at least one Gd-enhancing lesion on MRI within 6 months prior to randomization
• -Participants in Group A (ocrelizumab in the DBP) and Group B (fingolimod in the DBP) who, in the opinion of the investigator, may benefit from switching to ocrelizumab and who have completed the DBP with study treatment (ocrelizumab/fingolimod), may participate in the OLE period